Medical Journals

Prostate Cancer-specific Mortality After Radical Prostatectomy or External Beam Radiation Therapy in Men with 1 or More High-risk Factors.

Authors:
  • D’Amico Anthony V
  • Chen Ming-Hui
  • Catalona William J
  • Sun Leon
  • Roehl Kimberly A
  • Moul Judd W

From: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA. adamico@partners.org

Cancer

  • Publish Date: Jul 2007
  • ISSN: 0008-543X
  • Volume: 110
  • Issue: 1
  • Pages: 56-61
  • Medium: Print
  • Language: English
  • Citation (JAMA): D'Amico Anthony V, Chen Ming-Hui, Catalona William J, et al. Prostate Cancer-specific Mortality After Radical Prostatectomy or External Beam Radiation Therapy in Men with 1 or More High-risk Factors.. Cancer Jul 2007;110:56-61

Abstract

BACKGROUND: Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors. METHODS: The study cohort comprised 948 men who underwent RP (N = 660) or RT (N = 288) for localized prostate cancer between 1988 and 2004 and had at least 1 of the following high-risk factors: a prostate-specific antigen (PSA) velocity >2 ng/mL/year during the year before diagnosis, a biopsy Gleason score of >or=7, a PSA level of >or=10 ng/mL, or clinical category T2b or high disease. Grays regression was used to evaluate whether the number and type of high-risk factors were associated with time to PCSM. RESULTS: Multiple determinants of high risk were found to be significantly associated with a shorter time to PCSM after RP (P < .001) or RT (P 2 ng/mL/year was associated with an increased risk of PCSM after RP (hazards ratio [HR] of 7.3; 95% confidence interval [95% CI], 1.0-59 [P = .05]) or RT (HR of 12.1; 95% CI, 1.4-105 [P = .02]) when compared with men with any other single high-risk factor. CONCLUSIONS: Men with a PSA velocity >2 ng/mL/year had a significantly higher risk of PCSM compared with men who had any other single high-risk factor. These men should be considered for randomized trials evaluating the impact on PCSM from adding systemic agents to standards of care for men with high-risk PC.

Mesh Headings (Keywords): Aged, Cause of Death, Humans, Male, Middle Aged, Prostate, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Intensity-Modulated, Risk Factors, Survival Analysis, Survival Rate, Time Factors


Check for Full Text / PubMed Unique Identifier (PMID): 17530618


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.